Citi upgrades Myriad Genetics Inc (Nasdaq: MYGN) from Hold to Buy. Price target increased from $66 to $72.

This article: 122 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE